Find Imiquimod manufacturers, exporters & distributors on PharmaCompass

Virtual Booth

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

23 API Suppliers, 14 USDMF, 4 EU WC, 1 KDMF, 10 NDC API, 13 Listed Suppliers, $ API Reference Price

23 API Suppliers
14 USDMF
4 EU WC
1 KDMF
10 NDC API
13 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

3 Drugs in Development

3 Drugs in Development

INTERMEDIATES

4 Intermediates Suppliers

4 Intermediates Suppliers

FINISHED DOSAGE FORMULATIONS

46 FDF Dossiers, 13 FDA Orange Book, 10 Europe, 4 Canada, 11 Australia, 3 South Africa, 5 Listed Dossiers

46 FDF Dossiers
13 FDA Orange Book
10 Europe
4 Canada
11 Australia
3 South Africa
5 Listed Dossiers

RELATED EXCIPIENT COMPANIES

1 Rochem International Inc, 3 DKSH, 1 Pharm-RX Chemical, 4 Nanjing Well Pharmaceutical, 3 Actylis, 4 BASF, 1 Finar, 2 Gangwal Chemicals, 1 Kerry, 1 Microlex e.U, 1 Pluviaendo, 2 Seppic

relatedExcipients
1 Rochem International Inc
3 DKSH
1 Pharm-RX Chemical
4 Nanjing Well Pharmaceutical
3 Actylis
4 BASF
1 Finar
2 Gangwal Chemicals
1 Kerry
1 Microlex e.U
1 Pluviaendo
2 Seppic

EXCIPIENTS BY APPLICATIONS

13 Topical, 8 Solubilizers, 6 Emulsifying Agents, 6 Thickeners and Stabilizers, 5 Parenteral, 4 Surfactant & Foaming Agents, 2 Rheology Modifiers, 1 API Stability Enhancers, 1 Film Formers & Plasticizers, 1 Granulation, 1 Controlled & Modified Release, 1 Direct Compression, 1 Lubricants & Glidants, 1 Coating Systems & Additives

excipientsByApplications
13 Topical
8 Solubilizers
6 Emulsifying Agents
6 Thickeners and Stabilizers
5 Parenteral
4 Surfactant & Foaming Agents
2 Rheology Modifiers
1 API Stability Enhancers
1 Film Formers & Plasticizers
1 Granulation
1 Controlled & Modified Release
1 Direct Compression
1 Lubricants & Glidants
1 Coating Systems & Additives

DIGITAL CONTENT

2 DATA COMPILATION #PharmaFlow, 4 NEWS #PharmaBuzz

media
2 DATA COMPILATION #PharmaFlow
4 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

2 US Medicaid Prescriptions, 14 Finished Drug Prices

globalSalesInformation
2 US Medicaid Prescriptions
14 Finished Drug Prices

MARKET PLACE

4 APIs, 1 FDF Dossiers

marketPlace
4 APIs
1 FDF Dossiers

PATENTS & EXCLUSIVITIES

18 US Patents, 4 Health Canada Patents

patents
18 US Patents
4 Health Canada Patents

REF. STANDARDS & IMPURITIES

6 USP , 5 Others

otherSolutions
6 USP
5 Others

Imiquimod

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 2,560

MARKET PLACE

API

FDF

4INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

3DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

8,359,819

Annual Reports (USD Million)

Finished Drug Prices

24 RELATED EXCIPIENT COMPANIES

51EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 99011-02-6, Aldara, Zyclara, 1-isobutyl-1h-imidazo[4,5-c]quinolin-4-amine, 1-(2-methylpropyl)-1h-imidazo[4,5-c]quinolin-4-amine, Beselna

Molecular Formula

C₁₄H₁₆N₄

Molecular Weight

240.30 g/mol

InChI Key

DOUYETYNHWVLEO-UHFFFAOYSA-N

FDA UNII

P1QW714R7M

A topically-applied aminoquinoline immune modulator that induces interferon production. It is used in the treatment of external genital and perianal warts, superficial CARCINOMA, BASAL CELL; and ACTINIC KERATOSIS.

The mechanism of action of imiquimod is as an Interferon Inducer. The physiologic effect of imiquimod is by means of Increased Cytokine Activity, and Increased Cytokine Production.

1 2D Structure

Imiquimod

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

1-(2-methylpropyl)imidazo[4,5-c]quinolin-4-amine

2.1.2 InChI

InChI=1S/C14H16N4/c1-9(2)7-18-8-16-12-13(18)10-5-3-4-6-11(10)17-14(12)15/h3-6,8-9H,7H2,1-2H3,(H2,15,17)

2.1.3 InChI Key

DOUYETYNHWVLEO-UHFFFAOYSA-N

2.1.4 Canonical SMILES

CC(C)CN1C=NC2=C1C3=CC=CC=C3N=C2N

2.2 Other Identifiers

2.2.1 UNII

P1QW714R7M

2.3 Synonyms

2.3.1 MeSH Synonyms

1. 1-isobutyl-1h-imidazo(4,5-c)quinolin-4-amine

2. Aldara

3. R 837

4. R-837

5. R837

6. S 26308

7. S-26308

8. Zyclara

2.3.2 Depositor-Supplied Synonyms

1. 99011-02-6

2. Aldara

3. Zyclara

4. 1-isobutyl-1h-imidazo[4,5-c]quinolin-4-amine

5. 1-(2-methylpropyl)-1h-imidazo[4,5-c]quinolin-4-amine

6. Beselna

7. 4-amino-1-isobutyl-1h-imidazo[4,5-c]quinoline

8. R 837

9. 1-(2-methylpropyl)imidazo[4,5-c]quinolin-4-amine

10. 4-amino-1-isobutyl-1h-imidazo(4,5-c)quinoline

11. 9050-31-1

12. R-837

13. S-26308

14. C14h16n4

15. Mfcd00866946

16. Tmx-101

17. S26308

18. Nsc-369100

19. Nsc-759651

20. Chembl1282

21. 1-isobutylimidazo[4,5-c]quinolin-4-amine

22. P1qw714r7m

23. 1h-imidazo(4,5-c)quinolin-4-amine, 1-(2-methylpropyl)-

24. 1h-imidazo[4,5-c]quinolin-4-amine, 1-(2-methylpropyl)-

25. Chebi:36704

26. Ncgc00070736-02

27. Zartra

28. Imiquimod Acetate

29. Dsstox_cid_21047

30. Dsstox_rid_79617

31. Dsstox_gsid_41047

32. Aldara (tn)

33. Cas-99011-02-6

34. S 26308

35. Sr-01000611320

36. 1-(2-methylpropyl)-1h-imidazole[4,5-c]quinoline-4-amine

37. Unii-p1qw714r7m

38. Imiquimodum

39. Imiquimod [usan:inn:ban]

40. Vyloma

41. Mtd-39

42. Hsdb 8129

43. Tmx 101

44. Imiquimod,(s)

45. Imiquimod- Bio-x

46. 6t0

47. Imiquimod - Aldara

48. Zyclara (tn)

49. Dz-2636

50. R837

51. Imiquimod [inn]

52. Imiquimod [jan]

53. Imiquimod [mi]

54. Imiquimod [usan]

55. Imiquimod [vandf]

56. Imiquimod [mart.]

57. (non-labelled)imiquimod-d9

58. Imiquimod [usp-rs]

59. Imiquimod [who-dd]

60. Imiquimod (jan/usp/inn)

61. Schembl26136

62. Imiquimod [ema Epar]

63. Mls000083577

64. Bidd:gt0859

65. Gtpl5003

66. Imiquimod [orange Book]

67. Dtxsid7041047

68. Imiquimod [usp Monograph]

69. Hms2090m14

70. Hms2232g07

71. Hms3373b13

72. Hms3715n19

73. Hms3747a13

74. Pharmakon1600-01502351

75. Bcp05151

76. Hy-b0180

77. Tox21_110985

78. Ac-529

79. Bbl010772

80. Bdbm50240849

81. Nsc369100

82. Nsc759651

83. Nsc811538

84. S1211

85. Stk583860

86. Zinc19632912

87. Imiquimod - Cas 99011-02-6

88. Imiquimod, >=98% (hplc), Solid

89. Akos005507352

90. Cellulose, Hydrogen 1,2-benzenedicarboxylate, 2-hydroxypropyl Methyl Ether

91. Tox21_110985_1

92. 1h-imidazo[4, 1-(2-methylpropyl)-

93. Ccg-208015

94. Cs-2058

95. Db00724

96. Ks-5218

97. Nsc 369100

98. Nsc 741062

99. Nsc 759651

100. Nsc-811538

101. Yh44175

102. (hydroxypropyl)methyl Cellulose Phthalate

103. Imiquimod 100 Microg/ml In Acetonitrile

104. Ncgc00070736-03

105. Ncgc00070736-04

106. Bi164576

107. Smr000048307

108. Sy017571

109. Ft-0602727

110. I0747

111. D02500

112. 1-isobutyl-1h-imidazo [4,5-c]quinolin-4-amine

113. 1-isobutyl-1h-imidazo[4,5-c]quinoline-4-amine

114. Ab00399298-05

115. Ab00399298-06

116. Ab00399298-07

117. Ab00399298_08

118. Ab00399298_09

119. 011i026

120. 1-isobutyl-1h-imidazo[4,5-c]quinolin-4-ylamine

121. A845945

122. Q423417

123. 1-(2-methylpropyl)-4-imidazo[4,5-c]quinolinamine

124. Sr-01000611320-2

125. Sr-01000611320-3

126. Brd-k26657438-001-01-2

127. Brd-k26657438-001-13-7

128. 1-(2-methylpropyl)-1himidazo[4,5-c]quinolin-4-amine

129. 1-(2-methylpropyl)-1h-imidazo[4,5-c]-quinolin-4-amine

130. Imiquimod, United States Pharmacopeia (usp) Reference Standard

2.4 Create Date

2005-06-29

3 Chemical and Physical Properties

Molecular Formula	C₁₄H₁₆N₄
Molecular Weight	240.30 g/mol
XLogP3	2.6
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	3
Rotatable Bond Count	2
Exact Mass	240.137496527 g/mol
Monoisotopic Mass	240.137496527 g/mol
Topological Polar Surface Area	56.7 Å²
Heavy Atom Count	18
Formal Charge	0
Complexity	294
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Drug Information

1 of 6
Drug Name	Aldara
PubMed Health	Imiquimod (On the skin)
Drug Classes	Immune Modulator
Drug Label	Aldara (imiquimod 5%) Cream is an immune response modifier for topical administration. Each gram contains 50 mg of imiquimod in an off-white oil-in-water vanishing cream base consisting of isostearic acid, cetyl alcohol, stearyl alcohol, white petrol...
Active Ingredient	Imiquimod
Dosage Form	Cream
Route	Topical
Strength	5%
Market Status	Prescription
Company	Medicis

2 of 6
Drug Name	Imiquimod
PubMed Health	Imiquimod (On the skin)
Drug Classes	Immune Modulator
Drug Label	Aldara (imiquimod 5%) Cream is an immune response modifier for topical administration. Each gram contains 50 mg of imiquimod in an off-white oil-in-water vanishing cream base consisting of isostearic acid, cetyl alcohol, stearyl alcohol, white petrol...
Active Ingredient	Imiquimod
Dosage Form	Cream
Route	Topical
Strength	5%
Market Status	Prescription
Company	Apotex; Teva Pharms Usa; Taro; Strides Pharma; Glenmark Generics; Fougera Pharms; Tolmar; Perrigo Israel

3 of 6
Drug Name	Zyclara
PubMed Health	Imiquimod (On the skin)
Drug Classes	Immune Modulator
Drug Label	ZYCLARA (imiquimod) Cream, 2.5% or 3.75% is intended for topical administration. Each gram contains 25 mg or 37.5 mg of imiquimod, respectively, in a white to faintly yellow oil-in-water cream base consisting of isostearic acid, cetyl alcohol, steary...
Active Ingredient	Imiquimod
Dosage Form	Cream
Route	topical; Topical
Strength	3.75%; 2.5%
Market Status	Prescription
Company	Medicis; Graceway

4 of 6
Drug Name	Aldara
PubMed Health	Imiquimod (On the skin)
Drug Classes	Immune Modulator
Drug Label	Aldara (imiquimod 5%) Cream is an immune response modifier for topical administration. Each gram contains 50 mg of imiquimod in an off-white oil-in-water vanishing cream base consisting of isostearic acid, cetyl alcohol, stearyl alcohol, white petrol...
Active Ingredient	Imiquimod
Dosage Form	Cream
Route	Topical
Strength	5%
Market Status	Prescription
Company	Medicis

5 of 6
Drug Name	Imiquimod
PubMed Health	Imiquimod (On the skin)
Drug Classes	Immune Modulator
Drug Label	Aldara (imiquimod 5%) Cream is an immune response modifier for topical administration. Each gram contains 50 mg of imiquimod in an off-white oil-in-water vanishing cream base consisting of isostearic acid, cetyl alcohol, stearyl alcohol, white petrol...
Active Ingredient	Imiquimod
Dosage Form	Cream
Route	Topical
Strength	5%
Market Status	Prescription
Company	Apotex; Teva Pharms Usa; Taro; Strides Pharma; Glenmark Generics; Fougera Pharms; Tolmar; Perrigo Israel

6 of 6
Drug Name	Zyclara
PubMed Health	Imiquimod (On the skin)
Drug Classes	Immune Modulator
Drug Label	ZYCLARA (imiquimod) Cream, 2.5% or 3.75% is intended for topical administration. Each gram contains 25 mg or 37.5 mg of imiquimod, respectively, in a white to faintly yellow oil-in-water cream base consisting of isostearic acid, cetyl alcohol, steary...
Active Ingredient	Imiquimod
Dosage Form	Cream
Route	topical; Topical
Strength	3.75%; 2.5%
Market Status	Prescription
Company	Medicis; Graceway

4.2 Therapeutic Uses

Adjuvants, Immunologic; Antineoplastic Agents

National Library of Medicine's Medical Subject Headings online file (MeSH, 2013)

Imiquimod is used topically for the treatment of clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratosis on the face or scalp in immunocompetent adults; treatment of biopsy-confirmed, primary superficial basal cell carcinoma in immunocompetent adults; and treatment of external genital and perianal exophytic warts (condylomata acuminata) caused by human papillomavirus (HPV). /Included in US product label/

American Society of Health-System Pharmacists 2012; Drug Information 2012. Bethesda, MD. 2012, p. 3577

Topical imiquimod has been effective when used in a limited number of adults and children for the treatment of molluscum contagiosum. /NOT included in US product label/

American Society of Health-System Pharmacists 2012; Drug Information 2012. Bethesda, MD. 2012, p. 3578

Imiquimod 5% cream has been used for the topical treatment of external genital and perianal HPV warts in a limited number of adults with human immunodeficiency virus (HIV) infection; however, the response rate appears to be lower in these individuals than in those who are not HIV infected. /NOT included in US product label/

American Society of Health-System Pharmacists 2012; Drug Information 2012. Bethesda, MD. 2012, p. 3578

For more Therapeutic Uses (Complete) data for Imiquimod (6 total), please visit the HSDB record page.

4.3 Drug Warning

Adverse local reactions, including erythema, erosion, excoriation/flaking, and edema, commonly occur at the site of application of imiquimod and/or surrounding areas. These reactions usually are mild to moderate in severity; however, severe local reactions have been reported.

American Society of Health-System Pharmacists 2012; Drug Information 2012. Bethesda, MD. 2012, p. 3578

In controlled studies in adults with actinic keratosis, the most frequently reported local skin reactions in those receiving imiquimod 5% cream (twice weekly for 16 weeks) were erythema (97%), flaking/scaling/dryness (93%), scabbing/crusting (79%), edema (49%), erosion/ulceration (48%), weeping/exudate (22%), and vesicles (9%).1 Application site reactions (e.g., bleeding, burning, induration, irritation, pain, pruritus, stinging, tenderness) occurred in 33% of those receiving topical imiquimod compared with 14% of those receiving placebo. In these studies, 16% of patients discontinued imiquimod treatment because of local or application site reactions and 91% of these were able to resume treatment after a rest period.

American Society of Health-System Pharmacists 2012; Drug Information 2012. Bethesda, MD. 2012, p. 3578

Adverse dermatologic reactions at sites away from the site of application have been reported in some patients receiving topical imiquimod. Remote site reactions have included bleeding, burning, edema, erosion, erythema, excoriation/flaking, induration, pain, pruritus, tenderness, tinea cruris, and ulceration.

American Society of Health-System Pharmacists 2012; Drug Information 2012. Bethesda, MD. 2012, p. 3579

When imiquimod 5% cream was used in controlled studies in patients with genital and perianal HPV warts (3 times weekly for up to 16 weeks), erythema occurred in 58-65%, erosion in 30-31%, excoriation/flaking in 18-26%, edema in 12-18%, scabbing in 4-13%, induration in 5-7%, ulceration in 4-8%, and vesicles in 2-3% of those receiving the drug.1 In addition, application site reactions in those receiving the drug included pruritus (22-32%), burning (9-26%), pain (2-8%), and soreness (0-3%). In addition, fungal infections occurred in 2-11% of patients receiving the drug. Overall, 1.2% of patients in these studies discontinued treatment because of local or application site reactions.

American Society of Health-System Pharmacists 2012; Drug Information 2012. Bethesda, MD. 2012, p. 3579

For more Drug Warnings (Complete) data for Imiquimod (25 total), please visit the HSDB record page.

4.4 Drug Indication

For the topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses on the face or scalp in immunocompetent adults. Also indicated for the treatment of external genital and perianal warts/condyloma acuminata in individuals 12 years old and above.

FDA Label

Zyclara is indicated for the topical treatment of clinically typical, non-hyperkeratotic, non-hypertrophic, visible or palpable actinic keratosis of the full face or balding scalp in immunocompetent adults when other topical treatment options are contraindicated or less appropriate.

Imiquimod cream is indicated for the topical treatment of:

- external genital and perianal warts (condylomata acuminata) in adults;

- small superficial basal-cell carcinomas (sBCCs) in adults;

- clinically typical, non-hyperkeratotic, non-hypertrophic actinic keratoses (AKs) on the face or scalp in immunocompetent adult patients when size or number of lesions limit the efficacy and / or acceptability of cryotherapy and other topical treatment options are contraindicated or less appropriate.

Imiquimod cream is indicated for the topical treatment of external genital and perianal warts (condyloma acuminata) in adult patients.

5 Pharmacology and Biochemistry

5.1 Pharmacology

Imiquimod is an immune response modifier that acts as a toll-like receptor 7 agonist. Imiquimod is commonly used topically to treat warts on the skin of the genital and anal areas. Imiquimod does not cure warts, and new warts may appear during treatment. Imiquimod does not fight the viruses that cause warts directly, however, it does help to relieve and control wart production. It is not used on warts inside the vagina, penis, or rectum. Imiquimod is also used to treat a skin condition of the face and scalp called actinic keratoses. Imiquimod can also be used to treat certain types of skin cancer called superficial basal cell carcinoma. Imiquimod is particularly useful on areas where surgery or other treatments may be difficult, complicated or otherwise undesirable, especially the face and lower legs.

5.2 MeSH Pharmacological Classification

Adjuvants, Immunologic

Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. (See all compounds classified as Adjuvants, Immunologic.)

Antineoplastic Agents

Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)

Interferon Inducers

Agents that promote the production and release of interferons. They include mitogens, lipopolysaccharides, and the synthetic polymers Poly A-U and Poly I-C. Viruses, bacteria, and protozoa have been also known to induce interferons. (See all compounds classified as Interferon Inducers.)

5.3 FDA Pharmacological Classification

5.3.1 Active Moiety

IMIQUIMOD

5.3.2 FDA UNII

P1QW714R7M

5.3.3 Pharmacological Classes

Increased Cytokine Production [PE]; Interferon Inducers [MoA]; Increased Cytokine Activity [PE]

5.4 ATC Code

D06BB10

L03AX

D06BB10

S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355

D - Dermatologicals

D06 - Antibiotics and chemotherapeutics for dermatological use

D06B - Chemotherapeutics for topical use

D06BB - Antivirals

D06BB10 - Imiquimod

5.5 Absorption, Distribution and Excretion

Absorption

Well absorbed through skin (as a cream)

Following topical application to the skin in adults with actinic keratosis (75-mg doses 3 times weekly for 16 weeks), 0.08-0.15% of the dose is eliminated in urine as unchanged drug and metabolites. Following topical application in patients with HPV warts, 0.11 or 2.41% of the dose is eliminated in urine as unchanged drug and metabolites in men or women, respectively.

American Society of Health-System Pharmacists 2012; Drug Information 2012. Bethesda, MD. 2012, p. 3580

Imiquimod is absorbed systemically following topical application to skin. In adults with actinic keratosis who received topical imiquimod 5% cream 3 times weekly for 16 weeks, mean peak serum concentrations at the end of week 16 were approximately 0.1, 0.2, or 3.5 ng/mL in those treated on the face (12.5-mg doses), scalp (25-mg doses), or hands/arms (75-mg doses), respectively. Systemic exposure appeared to depend more on the surface area of the application site than on the total applied dose. In patients with external genital and perianal human papillomavirus (HPV) warts who received topical imiquimod 5% cream (average dose 4.6 mg), mean peak serum concentrations were 0.4 ng/mL.

American Society of Health-System Pharmacists 2012; Drug Information 2012. Bethesda, MD. 2012, p. 3580

5.6 Biological Half-Life

20 hours (topical dose), 2 hours (subcutaneous dose)

Studies using subcutaneous imiquimod indicate the drug has an apparent half-life of 2 hours. Following topical application, imiquimod appears to be retained in the skin for prolonged periods since the half-life is approximately 10 times greater than that reported following subcutaneous administration.

American Society of Health-System Pharmacists 2012; Drug Information 2012. Bethesda, MD. 2012, p. 3580

5.7 Mechanism of Action

Imiquimod's mechanism of action is via stimulation of innate and acquired immune responses, which ultimately leads to inflammatory cell infiltration within the field of drug application followed by apoptosis of diseased tissue. Imiquimod does not have direct antiviral activity. Studies of mice show that imiquimod may induce cytokines, including interferon-alpha (IFNA) as well as several IFNA genes (IFNA1, IFNA2, IFNA5, IFNA6, and IFNA8) as well as the IFNB gene. Imiquimod also induced the expression of interleukin (IL)-6, IL-8, and tumor necrosis factor alpha genes. In the treatment of basal cell carcinoma, Imiquimod appears to act as a toll-like receptor-7 agonist, and is thought to exert its anti-tumor effect via modification of the immune response and stimulation of apoptosis in BCC cells. In treating basal cell carcinoma it may increase the infiltration of lymphocytes, dendritic cells, and macrophages into the tumor lesion.

Imiquimod and resiquimod represent Toll-like receptor (TLR) 7 and 8 agonists, which emerged as attractive candidates for tumor therapy. To elucidate immune cells, which mainly contribute to TLR7/8-mediated antitumoral activity, /the researchers/ investigated the impact of imiquimod and resiquimod on native human 6-sulfo LacNAc (slan) dendritic cells (DCs). /The researchers/ found that both TLR7/8 agonists significantly improve the release of various proinflammatory cytokines by slanDCs and promote their tumor-directed cytotoxic activity. Furthermore, resiquimod efficiently augmented the ability of slanDCs to stimulate T cells and natural killer cells. These results indicate that imiquimod and resiquimod trigger various immunostimulatory properties of slanDCs, which may contribute to their antitumor effects.

PMID:23402811 Jahnisch H et al; Cancer Lett. 2013 Feb 9 (Epub ahead of print)

Aldara is a cream used for topical treatment of non-melanoma skin cancer, and is thought to act through stimulation of anti-tumour immunity. The active ingredient, imiquimod, has been shown to stimulate toll-like receptor 7. Aldara also induces psoriasis-like lesions when applied to naive murine skin, and as such is used as a mouse model for psoriasis. Here we find that in naive murine skin, Aldara induces inflammation largely independently of toll-like receptor 7. Surprisingly, inflammasome activation, keratinocyte death and interleukin 1 release also occur in response to the vehicle cream in the absence of imiquimod. We show that isostearic acid, a major component of the vehicle, promotes inflammasome activation in cultured keratinocytes, and so may contribute to the observed effects of Aldara on murine skin. Aldara therefore stimulates at least two immune pathways independently, and both imiquimod and vehicle are required for a full inflammatory response. Although it remains to be tested, it is possible that imiquimod-independent effects also contribute to the therapeutic efficacy of Aldara.

PMID:23463003 Walter A et al; Nat Commun. 2013 Mar 5;4:1560

Imiquimod is recognized as an agonist for Toll-like receptor 7 (TLR7) in immunocompetent cells. TLR7, as well as TLR3 and TLR8, triggers the immune responses, such as the production of type I interferons (IFNs) and proinflammatory cytokines via recognition of viral nucleic acids in the infected cells. In this study, /the reseachers/ proposed that imiquimod has an IFN-independent antiviral effect in nonimmune cells. Imiquimod, but not resiquimod, suppressed replication of human herpes simplex virus 1 (HSV-1) in FL cells. We analyzed alternation of gene expression by treatment with imiquimod using microarray analysis. Neither type I IFNs, nor TLRs, nor IFN-inducible antiviral genes were induced in imiquimod-treated FL cells. Cystatin A, a host cysteine protease inhibitor, was strongly upregulated by imiquimod and took a major part in the anti-HSV-1 activity deduced by the suppression experiment using its small interfering RNA. Upregulation of cystatin A was suggested to be mediated by antagonizing adenosine receptor A(1) and activating the protein kinase A pathway. Imiquimod, but not resiquimod, was shown to interact with adenosine receptor A(1). Imiquimod-induced anti-HSV-1 activity was observed in other cells, such as HeLa, SiHa, and CaSki cells, in a manner consistent with the cystatin A induction by imiquimod. These results indicated that imiquimod acted as an antagonist for adenosine receptor A(1) and induced a host antiviral protein, cystatin A. The process occurred independently of TLR7 and type I IFNs.

PMID:22787201 Full text: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3457300 Kan Y et al; J Virol 86 (19): 10338-46 (2012)

Toll-like receptor (TLR) agonists have anticancer effect by inducing apoptosis or activating immune cells. In this study, we investigated whether imiquimod, TLR7 agonist, inhibits the proliferation of oral cancer cells. Toll-like receptor 7 expression and IL-6/8 production by imiquimod were examined using RT-PCR and Enzyme-linked immunosorbent assay, respectively. Cell viability was examined by MTT assay. To examine apoptotic cell death, Annexin V/PI staining for flow cytometry and Western blot analysis were performed. Necrotic cell death was determined by leakage of lactate dehydrogenase (LDH), HMGB1, and PI staining in imiquimod-treated oral squamous cell carcinoma (OSCC) cells. Toll-like receptor 7 mRNA was expressed in OSCC cells. Imiquimod induced IL-6 and IL-8 production in OSCC cells, suggesting the functional expression of TLR7. Imiquimod inhibited cells proliferation in a dose-dependent manner. The ratio of annexin V-positive cells and cleaved caspase-3/7 was increased by imiquimod treatment in OSCC cells, suggesting that imiquimod-induced cell death in OSCC cells may be owing to apoptosis. In addition, LDH secretion and PI staining were detected in OSCC cells treated with imiquimod, showing that imiquimod also induced necrotic cell death in the OSCC cells. Imiquimod inhibited effectively the growth of OSCC cells by inducing apoptosis and necrosis.

PMID:22577802 Ahn MY et al; J Oral Pathol Med 41 (7): 540-6 (2012)

API SUPPLIERS

01

Interquim SA

Spain

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

DDL Conference

Not Confirmed

Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

Contact Supplier

Spain

Virtual Booth

Digital Content

USDMF

Click Us!

CEP/COS JDMF EU-WC NDC KDMF VMF ASMF

AUDIT

02

LGM Pharma

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

DDL Conference

Not Confirmed

LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

Contact Supplier

U.S.A

Virtual Booth

Digital Content

USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT

03

Seqens

France

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

DDL Conference

Not Confirmed

Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

Contact Supplier

France

Virtual Booth

Digital Content

USDMF

CEP/COS JDMF EU-WC NDC

KDMF VMF Others AUDIT

04

USV Private Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

DDL Conference

Not Confirmed

USV offers custom peptide synthesis ranging from gram to multi-gram to multi-kilogram quantities.

Contact Supplier

India

Virtual Booth

Digital Content

USDMF

CEP/COS JDMF EU-WC

NDC

KDMF VMF Others AUDIT

Portfolio PDF

05

TAPI Technology & API Services

Israel

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

CPhI WW Frankfurt

Booth #6.1A32

TAPI offers customized CDMO Solutions for API development and manufacturing services.

Contact Supplier

Israel

Virtual Booth

Digital Content

USDMF

CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT

Product Web Link

Corporate PDF

06

Solara Active Pharma Sciences

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

DDL Conference

Not Confirmed

07

Taro Pharmaceutical Industries

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

DDL Conference

Not Confirmed

08

Taro Pharmaceutical Industries

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

DDL Conference

Not Confirmed

09

Glenmark Life Sciences

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

DDL Conference

Not Confirmed

10

Wanbury Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

DDL Conference

Not Confirmed

Only 10 entries up to this point, click to access all

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

01

Interquim Sa

Spain

Antibody Engineering

Not Confirmed

Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

Contact Supplier

Spain

Virtual Booth

Digital Content

Imiquimod

GDUFA

DMF Review : Complete

Rev. Date : 2013-05-09

Pay. Date : 2013-04-26

DMF Number : 20247

Submission : 2007-02-07

Status : Active

Type : II

02

Wavelength Enterprises Ltd

France

Antibody Engineering

Not Confirmed

Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

Contact Supplier

France

Virtual Booth

Digital Content

Imiquimod

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 19009

Submission : 2005-12-05

Status : Active

Type : II

03

Usv Private Ltd

India

Antibody Engineering

Not Confirmed

USV offers custom peptide synthesis ranging from gram to multi-gram to multi-kilogram quantities.

Contact Supplier

India

Virtual Booth

Digital Content

Imiquimod Usp

GDUFA

DMF Review : Complete

Rev. Date : 2013-08-28

Pay. Date : 2013-08-16

DMF Number : 20353

Submission : 2007-04-05

Status : Active

Type : II

Portfolio PDF

04

Teva Pharmaceutical Industries Ltd

Israel

CPhI WW Frankfurt

Booth #6.1A32

TAPI offers customized CDMO Solutions for API development and manufacturing services.

Contact Supplier

Israel

Virtual Booth

Digital Content

Imiquimod

GDUFA

DMF Review : Complete

Rev. Date : 2012-11-23

Pay. Date : 2012-11-09

DMF Number : 19507

Submission : 2006-06-06

Status : Active

Type : II

Product Web Link

Corporate PDF

05

Actavis Group Ptc Ehf

Ireland

Antibody Engineering

Not Confirmed

06

Teva Pharmaceutical Industries Ltd

Ireland

Antibody Engineering

Not Confirmed

07

Amino Chemicals Ltd

Malta

Antibody Engineering

Not Confirmed

08

Glenmark Life Sciences Ltd

India

Antibody Engineering

Not Confirmed

09

Tai Heng Industry Co Ltd

China

Antibody Engineering

Not Confirmed

10

Taro Pharmaceutical Industries Ltd

U.S.A

Antibody Engineering

Not Confirmed

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

EU WC

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

KDMF

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

01

Interquim SA

Spain

AES 2024

Not Confirmed

Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

Contact Supplier

Spain

Virtual Booth

Digital Content

Imiquimod

About the Company : Interquim, founded in 1978, is now part of the Ferrer HealthTech division. Interquim specializes in the development of competitive processes for manufacturing high added-value APIs...

Interquim, founded in 1978, is now part of the Ferrer HealthTech division. Interquim specializes in the development of competitive processes for manufacturing high added-value APIs that meet stringent quality standards. Complying with European environmental and work safety regulations, Interquim’s products are exported to highly regulated pharmaceutical markets. Regulatory bodies and clients have approved its quality system and facilities. With state-of-the-art multi-production plants, drug synthesis, and quality-control labs, Interquim supports clients throughout the entire product lifecycle, from product development to marketing.

02

LGM Pharma

U.S.A

AES 2024

Not Confirmed

LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

Contact Supplier

U.S.A

Virtual Booth

Digital Content

Imiquimod

About the Company : LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for the pharmaceutical and biotech industries. LGM is also a full service CDMO providing formulation, ...

LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for the pharmaceutical and biotech industries. LGM is also a full service CDMO providing formulation, analytical method development and testing, and commercial manufacturing. LGM Pharma offers custom API synthesis, analytical development, and regulatory services. With a network of over 300 accredited CGMP manufacturing partners, LGM provides unparalleled supply chain security. And, with over 100,000 square feet of FDA-inspected cGMP manufacturing and warehouse capacity, LGM Pharma provides a one-stop solution for solid dose, powder, semi-solid and liquid drugs.

03

Seqens

France

AES 2024

Not Confirmed

Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

Contact Supplier

France

Virtual Booth

Digital Content

Imiquimod

About the Company : Since its inception in 2003, Seqens has grown to become a global leader in pharmaceutical solutions and specialty ingredients. Seqens supports its customers in developing, scaling ...

Since its inception in 2003, Seqens has grown to become a global leader in pharmaceutical solutions and specialty ingredients. Seqens supports its customers in developing, scaling up and manufacturing drug substances from the pre-clinical phase to the commercial phase. It offers a large portfolio of APIs and proprietary products. Seqens also develops custom solutions and ingredients for the most demanding industries, such as healthcare, electronics and cosmetics. Its unique range of technologies enables it to manufacture complex molecules for small- and large-scale demands. It operates 24 industrial plants and 10 R&D centres across the globe.

04

USV Private Limited

India

AES 2024

Not Confirmed

USV offers custom peptide synthesis ranging from gram to multi-gram to multi-kilogram quantities.

Contact Supplier

India

Virtual Booth

Digital Content

Imiquimod

About the Company : USV is a leading health care company with focus on Active Pharmaceutical Ingredients (marketed globally with emphasis on regulated markets of USA, European Union and Japan), Brande...

USV is a leading health care company with focus on Active Pharmaceutical Ingredients (marketed globally with emphasis on regulated markets of USA, European Union and Japan), Branded Generics and Bio-therapeutics. USV also specializes in Research and Development in Biotechnology, Drug Delivery and Chemistry.31 APIs are currently on offer, 13 are in advanced stages of development and 14 are under development. Segments covered include Diabetes, Cardiology, CNS, Oncology, Dermatology and Ophthalmology.

Portfolio PDF

05

Arch Pharmalabs

India

AES 2024

Not Confirmed

06

Glenmark Pharmaceuticals

India

AES 2024

Not Confirmed

07

Guangzhou Tosun Pharmaceutical

China

AES 2024

Not Confirmed

08

Solara Active Pharma Sciences

India

AES 2024

Not Confirmed

09

Teva Pharmaceutical Industries

Israel

AES 2024

Not Confirmed

10

Tocopharm Co. Limited

China

AES 2024

Not Confirmed

Tocopharm Co. Limited

China

AES 2024

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Post an Enquiry

China

Virtual Booth

Digital Content

Imiquimod

About the Company : Tocopharm Co. Limited, built in 2008,is an industry leader in the field of Active Pharmaceutical Ingredients(API), relative pharmaceutical intermediates, derivatives of Quinoline d...

Tocopharm Co. Limited, built in 2008,is an industry leader in the field of Active Pharmaceutical Ingredients(API), relative pharmaceutical intermediates, derivatives of Quinoline derivatives of Beta-cyclodextrin and custom synthesis services. We are specialized in exploring,researching and production of these chemicals. We are also able to provide our customers with professional services and products with high quality. Tocopharm is in possession of two R&D laboratories and two factories in mainland China. Our products are made to the strictest quality control standards and meet all government regulations. At Tocopharm, our ever increasing global presence has been achieved through world class customer service and our commitment to innovation. We work with each individual customer to develop a solution that not only meets their demands, it exceeds them.Our products have been widely sold to many countries and regions that we have established long-term stable relations of cooperation with the traders and end users all around the world and have become a solid bridge among the suppliers, traders and end users.

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

Only 10 entries up to this point, click to access all

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API Reference Price

[{"dataSource":"API Export","activeIngredients":"IMIQUIMOD","year":"2021","qtr":"Q2","strtotime":1617388200,"product":"IMIQUIMOD - BULK DRUG","address":"PLOT 170-172, CHANDRAMOULI,INDUSTR IAL ESTATE, MOHOL BAZARPETH","city":"SOLAPUR,MAHARASHTRA","supplier":"GLENMARK PHARMACEUTICALS","supplierCountry":"INDIA","foreign_port":"BOGOTA","customer":"MEGALABS COLOMBIA SAS","customerCountry":"COLOMBIA","quantity":"10.00","actualQuantity":"10","unit":"KGS","unitRateFc":"1386.7","totalValueFC":"13419.7","currency":"USD","unitRateINR":99908.5,"date":"03-Apr-2021","totalValueINR":"999085","totalValueInUsd":"13419.7","indian_port":"BOMBAY AIR","hs_no":"29339990","bill_no":"9863512","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"COLOMBIA","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"PLOT 170-172, CHANDRAMOULI,INDUSTR IAL ESTATE, MOHOL BAZARPETH, SOLAPUR,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"IMIQUIMOD","year":"2021","qtr":"Q2","strtotime":1619634600,"product":"IMIQUIMOD - BULK DRUG","address":"PLOT 170-172, CHANDRAMOULI,INDUSTR IAL ESTATE, MOHOL BAZARPETH","city":"SOLAPUR,MAHARASHTRA","supplier":"GLENMARK PHARMACEUTICALS","supplierCountry":"INDIA","foreign_port":"ASUNCION","customer":"QUIMFA S.A.","customerCountry":"PARAGUAY","quantity":"3.00","actualQuantity":"3","unit":"KGS","unitRateFc":"1500","totalValueFC":"4499.7","currency":"USD","unitRateINR":111666.66666666667,"date":"29-Apr-2021","totalValueINR":"335000","totalValueInUsd":"4499.7","indian_port":"BOMBAY AIR","hs_no":"29339990","bill_no":"1445075","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"PARAGUAY","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"PLOT 170-172, CHANDRAMOULI,INDUSTR IAL ESTATE, MOHOL BAZARPETH, SOLAPUR,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"IMIQUIMOD","year":"2021","qtr":"Q2","strtotime":1621362600,"product":"IMIQUIMOD - BULK DRUG","address":"PLOT 170-172, CHANDRAMOULI,INDUSTR IAL ESTATE, MOHOL BAZARPETH","city":"SOLAPUR,MAHARASHTRA","supplier":"GLENMARK PHARMACEUTICALS","supplierCountry":"INDIA","foreign_port":"MEXICO CITY","customer":"A.A. MARTIN RODRIGUEZ RUIZ","customerCountry":"MEXICO","quantity":"5.00","actualQuantity":"5","unit":"KGS","unitRateFc":"2896.3","totalValueFC":"14244.5","currency":"USD","unitRateINR":208680.20000000001,"date":"19-May-2021","totalValueINR":"1043401","totalValueInUsd":"14244.5","indian_port":"BOMBAY AIR","hs_no":"29339990","bill_no":"1870719","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"MEXICO","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"PLOT 170-172, CHANDRAMOULI,INDUSTR IAL ESTATE, MOHOL BAZARPETH, SOLAPUR,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"IMIQUIMOD","year":"2021","qtr":"Q2","strtotime":1621967400,"product":"IMIQUIMOD-USP BATCH NO:ADA000444A MFG DT :JAN 2018 RE TEST DT:DEC 2022","address":"NO.201, DEVAVRATA SECTOR 17,,VASHI , NAVI MUMBAI - 400705.","city":"NAVI MUMBAI,MAHARASHTRA","supplier":"SOLARA ACTIVE PHARMA SCIENCES","supplierCountry":"INDIA","foreign_port":"FRANKFURT\/MAIN INT\\'L","customer":"M\/S.","customerCountry":"GERMANY","quantity":"4.00","actualQuantity":"4","unit":"KGS","unitRateFc":"2911.4","totalValueFC":"11454.9","currency":"USD","unitRateINR":209765.07750000001,"date":"26-May-2021","totalValueINR":"839060.31","totalValueInUsd":"11454.9","indian_port":"BANGALORE AIR","hs_no":"29420090","bill_no":"2009858","productDescription":"API","marketType":"REGULATED MARKET","country":"GERMANY","selfForZScoreResived":"Pharma Grade","supplierPort":"BANGALORE AIR","supplierAddress":"NO.201, DEVAVRATA SECTOR 17,,VASHI , NAVI MUMBAI - 400705., NAVI MUMBAI,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q3","strtotime":1630348200,"product":"IMIQUIMOD - BULK DRUG","address":"PLOT 170-172, CHANDRAMOULI,INDUSTR IAL ESTATE, MOHOL BAZARPETH","city":"SOLAPUR,MAHARASHTRA","supplier":"GLENMARK PHARMACEUTICALS","supplierCountry":"INDIA","foreign_port":"MEXICO CITY","customer":"A.A. MARTIN RODRIGUEZ RUIZ","customerCountry":"MEXICO","quantity":"10.00","actualQuantity":"10","unit":"KGS","unitRateFc":"2900","totalValueFC":"28718.8","currency":"USD","unitRateINR":213000,"date":"31-Aug-2021","totalValueINR":"2130000","totalValueInUsd":"28718.8","indian_port":"BOMBAY AIR","hs_no":"29339990","bill_no":"4247810","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"MEXICO","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"PLOT 170-172, CHANDRAMOULI,INDUSTR IAL ESTATE, MOHOL BAZARPETH, SOLAPUR,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q3","strtotime":1631644200,"product":"IMIQUIMOD - BULK DRUG","address":"PLOT 170-172, CHANDRAMOULI,INDUSTR IAL ESTATE, MOHOL BAZARPETH","city":"SOLAPUR,MAHARASHTRA","supplier":"GLENMARK PHARMACEUTICALS","supplierCountry":"INDIA","foreign_port":"GUARULHOS","customer":"EMS","customerCountry":"BRAZIL","quantity":"5.00","actualQuantity":"5","unit":"KGS","unitRateFc":"2200","totalValueFC":"10808","currency":"USD","unitRateINR":159000,"date":"15-Sep-2021","totalValueINR":"795000","totalValueInUsd":"10808","indian_port":"BOMBAY AIR","hs_no":"29339990","bill_no":"4602289","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"BRAZIL","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"PLOT 170-172, CHANDRAMOULI,INDUSTR IAL ESTATE, MOHOL BAZARPETH, SOLAPUR,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q4","strtotime":1639938600,"product":"IMIQUIMOD","address":"Plot 170-172, Chandramouli Industrial Estate, Mohol Bazarpeth","city":"Solapur","supplier":"GLENMARK PHARMACEUTICALS","supplierCountry":"INDIA","foreign_port":"SANTIAGO DE CHILE -","customer":"SALCOBRAND S.A","customerCountry":"CHILE","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"2725","totalValueFC":"2717.9","currency":"USD","unitRateINR":205000,"date":"20-Dec-2021","totalValueINR":"205000","totalValueInUsd":"2717.9","indian_port":"BOMBAY AIR","hs_no":"29339990","bill_no":"6885609","productDescription":"API","marketType":"REGULATED MARKET","country":"CHILE","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"Plot 170-172, Chandramouli Industrial Estate, Mohol Bazarpeth, Solapur","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1642444200,"product":"IMIQUIMOD - BULK DRUG","address":"Plot 170-172, Chandramouli Industrial Estate, Mohol Bazarpeth","city":"Solapur","supplier":"GLENMARK PHARMACEUTICALS","supplierCountry":"INDIA","foreign_port":"ASUNCION","customer":"QUIMFA S.A.","customerCountry":"PARAGUAY","quantity":"5.00","actualQuantity":"5","unit":"KGS","unitRateFc":"1460","totalValueFC":"7208.7","currency":"USD","unitRateINR":107400,"date":"18-Jan-2022","totalValueINR":"537000","totalValueInUsd":"7208.7","indian_port":"BOMBAY AIR","hs_no":"29339990","bill_no":"7555498","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"PARAGUAY","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"Plot 170-172, Chandramouli Industrial Estate, Mohol Bazarpeth, Solapur","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1643826600,"product":"IMIQUIMOD","address":"PLOT 170-172, CHANDRAMOULI,INDUSTR","city":"SOLAPUR,MAHARASHTRA","supplier":"GLENMARK PHARMACEUTICALS","supplierCountry":"INDIA","foreign_port":"MONTEVIDEO","customer":"NPS URUGUAY S.A.","customerCountry":"URUGUAY","quantity":"23.00","actualQuantity":"23","unit":"KGS","unitRateFc":"1330","totalValueFC":"30036.2","currency":"USD","unitRateINR":97888,"date":"03-Feb-2022","totalValueINR":"2251424","totalValueInUsd":"30036.2","indian_port":"Dahez-SEZ","hs_no":"29339990","bill_no":"4001598","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"URUGAY","selfForZScoreResived":"Pharma Grade","supplierPort":"Dahez-SEZ","supplierAddress":"PLOT 170-172, CHANDRAMOULI,INDUSTR, SOLAPUR,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1644345000,"product":"IMIQUIMOD","address":"Plot 170-172, Chandramouli Industrial Estate, Mohol Bazarpeth","city":"Solapur","supplier":"GLENMARK PHARMACEUTICALS","supplierCountry":"INDIA","foreign_port":"SANTIAGO DE CHILE -","customer":"SALCOBRAND S.A","customerCountry":"CHILE","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"2725","totalValueFC":"2361.4","currency":"USD","unitRateINR":177000,"date":"09-Feb-2022","totalValueINR":"177000","totalValueInUsd":"2361.4","indian_port":"BOMBAY AIR","hs_no":"29339990","bill_no":"8087755","productDescription":"API","marketType":"REGULATED MARKET","country":"CHILE","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"Plot 170-172, Chandramouli Industrial Estate, Mohol Bazarpeth, Solapur","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1648405800,"product":"IMIQUIMOD","address":"PLOT 170-172, CHANDRAMOULI,INDUSTR","city":"SOLAPUR,MAHARASHTRA","supplier":"GLENMARK PHARMACEUTICALS","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES","customer":"RIHU HEALTHCARE CO., LTD.","customerCountry":"ARGENTINA","quantity":"10.00","actualQuantity":"10","unit":"KGS","unitRateFc":"1805","totalValueFC":"17808.6","currency":"USD","unitRateINR":135736,"date":"28-Mar-2022","totalValueINR":"1357360","totalValueInUsd":"17808.6","indian_port":"Dahez-SEZ","hs_no":"29339990","bill_no":"4004070","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"Dahez-SEZ","supplierAddress":"PLOT 170-172, CHANDRAMOULI,INDUSTR, SOLAPUR,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1648492200,"product":"IMIQUIMOD USP (MICRONISED) BATCH NO. 210","address":"ARVIND VITHAL GANDHI CHOWK, B.S.D.MARG, GOVANDI STATION ROAD Co","city":"MUMBAI","supplier":"USV PRIVATE LIMITED","supplierCountry":"INDIA","foreign_port":"CINCINNATI, OH","customer":"LGM PHARMA","customerCountry":"UNITED STATES","quantity":"26.44","actualQuantity":"26.44","unit":"KGS","unitRateFc":"2400","totalValueFC":"62582.4","currency":"USD","unitRateINR":180408.47201210287,"date":"29-Mar-2022","totalValueINR":"4770000","totalValueInUsd":"62582.4","indian_port":"BOMBAY AIR","hs_no":"29359090","bill_no":"9324458","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Micronized","supplierPort":"BOMBAY AIR","supplierAddress":"ARVIND VITHAL GANDHI CHOWK, B.S.D.MARG, GOVANDI STATION ROAD Co, MUMBAI","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1648665000,"product":"IMIQUIMOD - USP BATCH NO:MBPC21001A MFG","address":"NO.201, DEVAVRATA SECTOR 17, VASHI, NAVI MUMBAI - 400705. Contac","city":"NAVI MUMBAI","supplier":"SOLARA ACTIVE PHARMA SCIENCES","supplierCountry":"INDIA","foreign_port":"ANKARA","customer":"M\/S","customerCountry":"TURKEY","quantity":"1.50","actualQuantity":"1.5","unit":"KGS","unitRateFc":"4000","totalValueFC":"5628.5","currency":"USD","unitRateINR":286000,"date":"31-Mar-2022","totalValueINR":"429000","totalValueInUsd":"5628.5","indian_port":"BANGALORE AIR","hs_no":"29420090","bill_no":"9385591","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"BANGALORE AIR","supplierAddress":"NO.201, DEVAVRATA SECTOR 17, VASHI, NAVI MUMBAI - 400705. Contac, NAVI MUMBAI","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1649097000,"product":"IMIQUIMOD","address":"PLOT 170-172, CHANDRAMOULI,INDUSTR","city":"SOLAPUR,MAHARASHTRA","supplier":"GLENMARK PHARMACEUTICALS","supplierCountry":"INDIA","foreign_port":"SANTIAGO","customer":"ITF LABOMED FARMACEUTICA ","customerCountry":"CHILE","quantity":"13.00","actualQuantity":"13","unit":"KGS","unitRateFc":"1368","totalValueFC":"17725.3","currency":"USD","unitRateINR":102873.61538461539,"date":"05-Apr-2022","totalValueINR":"1337357","totalValueInUsd":"17725.3","indian_port":"Dahez-SEZ","hs_no":"29339990","bill_no":"4004456","productDescription":"API","marketType":"REGULATED MARKET","country":"CHILE","selfForZScoreResived":"Pharma Grade","supplierPort":"Dahez-SEZ","supplierAddress":"PLOT 170-172, CHANDRAMOULI,INDUSTR, SOLAPUR,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1653935400,"product":"IMIQUIMOD *LUT ARN NO. AD240322035753E D","address":"Plot 170-172, Chandramouli Industrial Estate, Mohol Bazarpeth","city":"Solapur","supplier":"GLENMARK PHARMACEUTICALS","supplierCountry":"INDIA","foreign_port":"MEXICO CITY","customer":"TO THE ORDER","customerCountry":"MEXICO","quantity":"5.00","actualQuantity":"5","unit":"KGS","unitRateFc":"2900","totalValueFC":"14414","currency":"USD","unitRateINR":222800,"date":"31-May-2022","totalValueINR":"1114000","totalValueInUsd":"14414","indian_port":"BOMBAY AIR","hs_no":"29339990","bill_no":"1793785","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"MEXICO","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"Plot 170-172, Chandramouli Industrial Estate, Mohol Bazarpeth, Solapur","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1655231400,"product":"IMIQUIMOD *LUT ARN NO. AD240322035753E D","address":"Plot 170-172, Chandramouli Industrial Estate, Mohol Bazarpeth","city":"Solapur","supplier":"GLENMARK PHARMACEUTICALS","supplierCountry":"INDIA","foreign_port":"MEXICO CITY","customer":"TO THE ORDER","customerCountry":"MEXICO","quantity":"5.00","actualQuantity":"5","unit":"KGS","unitRateFc":"2900","totalValueFC":"14266.4","currency":"USD","unitRateINR":222600,"date":"15-Jun-2022","totalValueINR":"1113000","totalValueInUsd":"14266.4","indian_port":"BOMBAY AIR","hs_no":"29339990","bill_no":"2147064","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"MEXICO","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"Plot 170-172, Chandramouli Industrial Estate, Mohol Bazarpeth, Solapur","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1655231400,"product":"IMIQUIMOD *LUT ARN NO. AD240322035753E D","address":"Plot 170-172, Chandramouli Industrial Estate, Mohol Bazarpeth","city":"Solapur","supplier":"GLENMARK PHARMACEUTICALS","supplierCountry":"INDIA","foreign_port":"MEXICO CITY","customer":"TO THE ORDER","customerCountry":"MEXICO","quantity":"10.00","actualQuantity":"10","unit":"KGS","unitRateFc":"2900","totalValueFC":"28532.9","currency":"USD","unitRateINR":222600,"date":"15-Jun-2022","totalValueINR":"2226000","totalValueInUsd":"28532.9","indian_port":"BOMBAY AIR","hs_no":"29339990","bill_no":"2147058","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"MEXICO","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"Plot 170-172, Chandramouli Industrial Estate, Mohol Bazarpeth, Solapur","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1656700200,"product":"IMIQUIMOD USP BATCH NO. 21002525","address":"ARVIND VITHAL GANDHI CHOWK, B.S.D.MARG, GOVANDI STATION ROAD Co","city":"MUMBAI","supplier":"USV PRIVATE LIMITED","supplierCountry":"INDIA","foreign_port":"CINCINNATI, OH","customer":"LGM PHARMA","customerCountry":"UNITED STATES","quantity":"17.00","actualQuantity":"17","unit":"KGS","unitRateFc":"2400","totalValueFC":"38218.5","currency":"USD","unitRateINR":178764.70588235295,"date":"02-Jul-2022","totalValueINR":"3039000","totalValueInUsd":"38218.5","indian_port":"BOMBAY AIR","hs_no":"29359090","bill_no":"2554696","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"ARVIND VITHAL GANDHI CHOWK, B.S.D.MARG, GOVANDI STATION ROAD Co, MUMBAI","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1669746600,"product":"IMIQUIMOD - USP (BATCH NO.MBPC21001A, MF","address":"NO.201, DEVAVRATA SECTOR 17, VASHI, NAVI MUMBAI - 400705. Contac","city":"NAVI MUMBAI","supplier":"SOLARA ACTIVE PHARMA SCIENCES","supplierCountry":"INDIA","foreign_port":"DUBAI","customer":"M\/S,","customerCountry":"UNITED ARAB EMIRATES","quantity":"2.20","actualQuantity":"2.2","unit":"KGS","unitRateFc":"2649","totalValueFC":"4815.4","currency":"EUR","unitRateINR":178636.36363636362,"date":"30-Nov-2022","totalValueINR":"393000","totalValueInUsd":"4815.4","indian_port":"BOMBAY AIR","hs_no":"29420090","bill_no":"5833294","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"UNITED ARAB EMIRATES","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"NO.201, DEVAVRATA SECTOR 17, VASHI, NAVI MUMBAI - 400705. Contac, NAVI MUMBAI","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1691346600,"product":"IMIQUIMOD-USP BATCH NO. MBPC21001A MANUFACTURING","address":"NA","city":"","supplier":"SOLARA ACTIVE PHARMA SCIENCES","supplierCountry":"INDIA","foreign_port":"DUBAI","customer":"KINGS MARQUE INTERNATIONAL ","customerCountry":"UNITED ARAB EMIRATES","quantity":"3.50","actualQuantity":"3.5","unit":"KGS","unitRateFc":"2600","totalValueFC":"9746.7","currency":"EUR","unitRateINR":230680.476,"date":"07-Aug-2023","totalValueINR":"807381.666","totalValueInUsd":"9746.7","indian_port":"DELHI AIR","hs_no":"29420090","bill_no":"0","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"UNITED ARAB EMIRATES","selfForZScoreResived":"Pharma Grade","supplierPort":"DELHI AIR","supplierAddress":"NA, ","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1691519400,"product":"IMIQUIMOD USP","address":"NA","city":"","supplier":"GLOBAUX IMPEX PRIVATE LIMITED","supplierCountry":"INDIA","foreign_port":"TORONTO","customer":"Z TO ORDER AND NA","customerCountry":"CANADA","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"3100","totalValueFC":"3060.2","currency":"USD","unitRateINR":253491.96599999999,"date":"09-Aug-2023","totalValueINR":"253491.966","totalValueInUsd":"3060.2","indian_port":"AHMEDABAD AIR","hs_no":"29339990","bill_no":"0","productDescription":"API","marketType":"REGULATED MARKET","country":"CANADA","selfForZScoreResived":"Pharma Grade","supplierPort":"AHMEDABAD AIR","supplierAddress":"NA, ","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1691519400,"product":"IMIQUIMOD-USP","address":"NA","city":"","supplier":"SOLARA ACTIVE PHARMA SCIENCES","supplierCountry":"INDIA","foreign_port":"OP HONG KONG","customer":"MS","customerCountry":"HONG KONG","quantity":"5.00","actualQuantity":"5","unit":"KGS","unitRateFc":"4000","totalValueFC":"21421.1","currency":"EUR","unitRateINR":354888.7524,"date":"09-Aug-2023","totalValueINR":"1774443.762","totalValueInUsd":"21421.1","indian_port":"BOMBAY AIR","hs_no":"29420090","bill_no":"0","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"HONG KONG","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"NA, ","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1695148200,"product":"IMIQUIMOD-USP, BATCH NO. MBPC23001A , MFG DT-AUG,2023, RETEST DT- JUL,2028","address":"NO.201, DEVAVRATA SECTOR 17,,VASHI","city":"NAVI MUMBAI,MAHARASHTRA","supplier":"SOLARA ACTIVE PHARMA SCIENCES","supplierCountry":"INDIA","foreign_port":"DUBAI","customer":"KINGS MARQUE INTERNATIONAL ","customerCountry":"UNITED ARAB EMIRATES","quantity":"8.50","actualQuantity":"8.5","unit":"KGS","unitRateFc":"2600","totalValueFC":"23323","currency":"EUR","unitRateINR":227764.70588235295,"date":"20-Sep-2023","totalValueINR":"1936000","totalValueInUsd":"23323","indian_port":"Delhi Air","hs_no":"29420090","bill_no":"4043408","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"UNITED ARAB EMIRATES","selfForZScoreResived":"Pharma Grade","supplierPort":"Delhi Air","supplierAddress":"NO.201, DEVAVRATA SECTOR 17,,VASHI, NAVI MUMBAI,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1695925800,"product":"ACTIVE PHARMACEUTICALS INGREDIENTS (API)EXPORT INVOICE NUMBER : F32418002521 DT. 21.09.2023 IMIQUIMOD","address":"PLOT 170-172, CHANDRAMOULI,INDUSTR","city":"SOLAPUR,MAHARASHTRA","supplier":"GLENMARK PHARMACEUTICALS","supplierCountry":"INDIA","foreign_port":"GUARULHOS","customer":"TO THE ORDER","customerCountry":"BRAZIL","quantity":"4.00","actualQuantity":"4","unit":"KGS","unitRateFc":"2420","totalValueFC":"9601.5","currency":"USD","unitRateINR":199250,"date":"29-Sep-2023","totalValueINR":"797000","totalValueInUsd":"9601.5","indian_port":"Bombay Air","hs_no":"29339990","bill_no":"4292342","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"BRAZIL","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"PLOT 170-172, CHANDRAMOULI,INDUSTR, SOLAPUR,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1699468200,"product":"ACTIVE PHARMACEUTICALS INGREDIENTS (API)EXPORT INVOICE NUMBER: F32418002659 DT.29.09.2023 IMIQUIMOD","address":"PLOT 170-172, CHANDRAMOULI,INDUSTR","city":"SOLAPUR,MAHARASHTRA","supplier":"GLENMARK PHARMACEUTICALS","supplierCountry":"INDIA","foreign_port":"MEXICO CITY","customer":"TO THE ORDER","customerCountry":"MEXICO","quantity":"5.00","actualQuantity":"5","unit":"KGS","unitRateFc":"2900","totalValueFC":"14338.7","currency":"USD","unitRateINR":238800,"date":"09-Nov-2023","totalValueINR":"1194000","totalValueInUsd":"14338.7","indian_port":"Bombay Air","hs_no":"29339990","bill_no":"5252904","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"MEXICO","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"PLOT 170-172, CHANDRAMOULI,INDUSTR, SOLAPUR,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1699813800,"product":"ACTIVE PHARMACEUTICALS INGREDIENTS (API)EXPORT INVOICE NUMBER : F32418002963 DT. 17.10.2023 IMIQUIMOD","address":"PLOT 170-172, CHANDRAMOULI,INDUSTR","city":"SOLAPUR,MAHARASHTRA","supplier":"GLENMARK PHARMACEUTICALS","supplierCountry":"INDIA","foreign_port":"MEXICO CITY","customer":"TO THE ORDER","customerCountry":"MEXICO","quantity":"5.00","actualQuantity":"5","unit":"KGS","unitRateFc":"2900","totalValueFC":"14290.7","currency":"USD","unitRateINR":238000,"date":"13-Nov-2023","totalValueINR":"1190000","totalValueInUsd":"14290.7","indian_port":"Bombay Air","hs_no":"29339990","bill_no":"5332312","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"MEXICO","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"PLOT 170-172, CHANDRAMOULI,INDUSTR, SOLAPUR,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1700245800,"product":"IMIQUIMOD-USP, BATCH NO.MBPC23001A, MFGDT-AUG\/2023, EXP DT-JUL\/2028","address":"NO.201, DEVAVRATA SECTOR 17,,VASHI","city":"NAVI MUMBAI,MAHARASHTRA","supplier":"SOLARA ACTIVE PHARMA SCIENCES","supplierCountry":"INDIA","foreign_port":"DUBAI","customer":"M\/S.","customerCountry":"UNITED ARAB EMIRATES","quantity":"7.60","actualQuantity":"7.6","unit":"KGS","unitRateFc":"2600","totalValueFC":"21027.8","currency":"EUR","unitRateINR":230394.73684210528,"date":"18-Nov-2023","totalValueINR":"1751000","totalValueInUsd":"21027.8","indian_port":"Delhi Air","hs_no":"29420090","bill_no":"5423164","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"UNITED ARAB EMIRATES","selfForZScoreResived":"Pharma Grade","supplierPort":"Delhi Air","supplierAddress":"NO.201, DEVAVRATA SECTOR 17,,VASHI, NAVI MUMBAI,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1701282600,"product":"IMIQUIMOD USP (MICRONISED)","address":"B.S.D.MARG, GOVANDI STATION ROAD,","city":"MUMBAI, MAHARASHTRA.","supplier":"USV PRIVATE LIMITED","supplierCountry":"INDIA","foreign_port":"TEL AVIV YAFO","customer":"PADAGIS ISRAEL PHARMACEUTICALS","customerCountry":"ISRAEL","quantity":"39.74","actualQuantity":"39.74","unit":"KGS","unitRateFc":"3030","totalValueFC":"119081.2","currency":"USD","unitRateINR":249521.89229994966,"date":"30-Nov-2023","totalValueINR":"9916000","totalValueInUsd":"119081.2","indian_port":"Bombay Air","hs_no":"29359090","bill_no":"5686217","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"ISRAEL","selfForZScoreResived":"Micronized","supplierPort":"Bombay Air","supplierAddress":"B.S.D.MARG, GOVANDI STATION ROAD,, MUMBAI, MAHARASHTRA.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1709145000,"product":"IMIQUIMOD-USP - BATCH NO:MBPC24001A, MFGDATE-FEB 2024, RE TEST DT:JAN-2029","address":"NO.201, DEVAVRATA SECTOR 17,,VASHI","city":"NAVI MUMBAI,MAHARASHTRA","supplier":"SOLARA ACTIVE PHARMA SCIENCES","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"M\/S","customerCountry":"TURKEY","quantity":"3.00","actualQuantity":"3","unit":"KGS","unitRateFc":"3400","totalValueFC":"9755.8","currency":"USD","unitRateINR":269825.60999999999,"date":"29-Feb-2024","totalValueINR":"809476.83","totalValueInUsd":"9755.8","indian_port":"Bangalore Air","hs_no":"29420090","bill_no":"7938623","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"Bangalore Air","supplierAddress":"NO.201, DEVAVRATA SECTOR 17,,VASHI, NAVI MUMBAI,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1711564200,"product":"IMIQUIMOD-USP BATCH NO:MBPC23001A ,24001A MFG DT:AUG 2023,FEB 2024 RE TEST DT:JULY 2028,JAN 2029","address":"NO.201, DEVAVRATA SECTOR 17,,VASHI","city":"NAVI MUMBAI,MAHARASHTRA","supplier":"SOLARA ACTIVE PHARMA SCIENCES","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"M\/S","customerCountry":"TURKEY","quantity":"6.00","actualQuantity":"6","unit":"KGS","unitRateFc":"2750","totalValueFC":"15151.4","currency":"USD","unitRateINR":209685.40833333333,"date":"28-Mar-2024","totalValueINR":"1258112.45","totalValueInUsd":"15151.4","indian_port":"Bangalore Air","hs_no":"29420090","bill_no":"8711822","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"Bangalore Air","supplierAddress":"NO.201, DEVAVRATA SECTOR 17,,VASHI, NAVI MUMBAI,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1714156200,"product":"IMIQUIMOD-USP, BATCH NO.MBPC24001A, MFGDT-FEB\/2024, EXP DT-JAN\/2029","address":"NO.201, DEVAVRATA SECTOR 17,,VASHI","city":"NAVI MUMBAI,MAHARASHTRA","supplier":"SOLARA ACTIVE PHARMA SCIENCES","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"M\/S","customerCountry":"TURKEY","quantity":"4.00","actualQuantity":"4","unit":"KGS","unitRateFc":"2470.5","totalValueFC":"9786.5","currency":"USD","unitRateINR":204310.35000000001,"date":"27-Apr-2024","totalValueINR":"817241.4","totalValueInUsd":"9786.5","indian_port":"Delhi Air","hs_no":"29420090","bill_no":"9440702","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"Delhi Air","supplierAddress":"NO.201, DEVAVRATA SECTOR 17,,VASHI, NAVI MUMBAI,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1714501800,"product":"ACTIVE PHARMACEUTICALS INGREDIENTS (API)EXPORT INVOICE NUMBER :F32518000299 DT.25.04.2024 IMIQUIMOD","address":"PLOT 170-172, CHANDRAMOULI,INDUSTR","city":"SOLAPUR,MAHARASHTRA","supplier":"GLENMARK PHARMACEUTICALS","supplierCountry":"INDIA","foreign_port":"SANTIAGO DE CHILE -","customer":"TO THE ORDER","customerCountry":"CHILE","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"2750","totalValueFC":"2400.6","currency":"USD","unitRateINR":200096.79000000001,"date":"01-May-2024","totalValueINR":"200096.79","totalValueInUsd":"2400.6","indian_port":"Bombay Air","hs_no":"29339990","bill_no":"9550117","productDescription":"API","marketType":"REGULATED MARKET","country":"CHILE","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"PLOT 170-172, CHANDRAMOULI,INDUSTR, SOLAPUR,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1726425000,"product":"ACTIVE PHARMACEUTICALS INGREDIENTS(API)EXPORT INVOICE NUMBER : F32512200636 DT.11.09.2024 IMIQUIMOD","address":"PLOT 170-172, CHANDRAMOULI,INDUSTR","city":"SOLAPUR,MAHARASHTRA","supplier":"GLENMARK PHARMACEUTICALS","supplierCountry":"INDIA","foreign_port":"BOGOT\u00c1, CUN","customer":"TO THE ORDER","customerCountry":"COLOMBIA","quantity":"10.00","actualQuantity":"10","unit":"KGS","unitRateFc":"1428","totalValueFC":"13921","currency":"USD","unitRateINR":116659.45,"date":"16-Sep-2024","totalValueINR":"1166594.5","totalValueInUsd":"13921","indian_port":"Dahez-SEZ","hs_no":"29339990","bill_no":"4030618","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"COLOMBIA","selfForZScoreResived":"Pharma Grade","supplierPort":"Dahez-SEZ","supplierAddress":"PLOT 170-172, CHANDRAMOULI,INDUSTR, SOLAPUR,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1727116200,"product":"ACTIVE PHARMACEUTICALS INGREDIENTS (API)EXPORT INVOICE NUMBER : F32518002264 DT. 18.09.2024 IMIQUIMOD","address":"PLOT 170-172, CHANDRAMOULI,INDUSTR","city":"SOLAPUR,MAHARASHTRA","supplier":"GLENMARK PHARMACEUTICALS","supplierCountry":"INDIA","foreign_port":"GUARULHOS","customer":"TO THE ORDER","customerCountry":"BRAZIL","quantity":"2.00","actualQuantity":"2","unit":"KGS","unitRateFc":"2420","totalValueFC":"4787.9","currency":"USD","unitRateINR":200618,"date":"24-Sep-2024","totalValueINR":"401236","totalValueInUsd":"4787.9","indian_port":"Bombay Air","hs_no":"29339990","bill_no":"4300954","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"BRAZIL","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"PLOT 170-172, CHANDRAMOULI,INDUSTR, SOLAPUR,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1729621800,"product":"ACTIVE PHARMACEUTICALS INGREDIENTS (API)EXPORT INVOICE NUMBER : F32518002841 DT. 21.10.2024 IMIQUIMOD","address":"PLOT 170-172, CHANDRAMOULI,INDUSTR","city":"SOLAPUR,MAHARASHTRA","supplier":"GLENMARK PHARMACEUTICALS","supplierCountry":"INDIA","foreign_port":"GUARULHOS","customer":"TO THE ORDER","customerCountry":"BRAZIL","quantity":"3.00","actualQuantity":"3","unit":"KGS","unitRateFc":"2420","totalValueFC":"7188.6","currency":"USD","unitRateINR":201344,"date":"23-Oct-2024","totalValueINR":"604032","totalValueInUsd":"7188.6","indian_port":"Bombay Air","hs_no":"29339990","bill_no":"5047178","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"BRAZIL","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"PLOT 170-172, CHANDRAMOULI,INDUSTR, SOLAPUR,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1729621800,"product":"ACTIVE PHARMACEUTICALS INGREDIENTS (API)EXPORT INVOICE NUMBER : F32518002842 DT. 21.10.2024 IMIQUIMOD","address":"PLOT 170-172, CHANDRAMOULI,INDUSTR","city":"SOLAPUR,MAHARASHTRA","supplier":"GLENMARK PHARMACEUTICALS","supplierCountry":"INDIA","foreign_port":"GUARULHOS","customer":"TO THE ORDER","customerCountry":"BRAZIL","quantity":"2.00","actualQuantity":"2","unit":"KGS","unitRateFc":"2420","totalValueFC":"4792.4","currency":"USD","unitRateINR":201344,"date":"23-Oct-2024","totalValueINR":"402688","totalValueInUsd":"4792.4","indian_port":"Bombay Air","hs_no":"29339990","bill_no":"5066067","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"BRAZIL","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"PLOT 170-172, CHANDRAMOULI,INDUSTR, SOLAPUR,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1729881000,"product":"ACTIVE PHARMACEUTICALS INGREDIENTS (API)EXPORT INVOICE NUMBER : F32512200804 DT25.10.2024 IMIQUIMOD USP","address":"PLOT 170-172, CHANDRAMOULI,INDUSTR","city":"SOLAPUR,MAHARASHTRA","supplier":"GLENMARK PHARMACEUTICALS","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES","customer":"TO THE ORDER","customerCountry":"ARGENTINA","quantity":"15.00","actualQuantity":"15","unit":"KGS","unitRateFc":"1150","totalValueFC":"16832.8","currency":"USD","unitRateINR":94293.333333333328,"date":"26-Oct-2024","totalValueINR":"1414400","totalValueInUsd":"16832.8","indian_port":"Dahez-SEZ","hs_no":"29339990","bill_no":"5163710","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"Dahez-SEZ","supplierAddress":"PLOT 170-172, CHANDRAMOULI,INDUSTR, SOLAPUR,MAHARASHTRA","customerAddress":""},{"dataSource":"API Import","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1689186600,"product":"IMIQUIMOD (FOR R & D)","address":"803, 8TH FLOOR,,HDIL B WING, KALED ONIA, SAHAR ROAD,","city":"MUMBAI,MAHARASHTRA","supplier":"INTERQUIM SA","supplierCountry":"SPAIN","foreign_port":"NA","customer":"ENCUBE ETHICALS PRIVATE LIMITED","customerCountry":"INDIA","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"12000","totalValueFC":"13279.1","currency":"EUR","unitRateINR":"1091399.9","date":"13-Jul-2023","totalValueINR":"1091399.932","totalValueInUsd":"13279.1","indian_port":"BOMBAY AIR","hs_no":"29339990","bill_no":"0","productDescription":"API","marketType":"REGULATED MARKET","country":"SPAIN","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"803, 8TH FLOOR,,HDIL B WING, KALED ONIA, SAHAR ROAD,"}]